These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33870432)

  • 61. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.
    Penna A; Laccabue D; Libri I; Giuberti T; Schivazappa S; Alfieri A; Mori C; Canetti D; Lampertico P; Viganò M; Colombo M; Loggi E; Missale G; Ferrari C
    J Hepatol; 2012 Jun; 56(6):1239-46. PubMed ID: 22326467
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
    Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure.
    Chen Q; Zhang J; Huang J; Quan B; Wu X; Deng S; Han W
    Med Sci Monit; 2019 Jun; 25():4665-4674. PubMed ID: 31230063
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.
    Tatsukawa Y; Tsuge M; Kawakami Y; Hiyama Y; Murakami E; Kurihara M; Nomura M; Tsushima K; Uchida T; Nakahara T; Miki D; Kawaoka T; Abe-Chayama H; Imamura M; Aikata H; Ochi H; Hayes CN; Kawakami H; Chayama K
    Antivir Ther; 2018; 23(8):639-646. PubMed ID: 29856363
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
    Chen X; Cao Z; Liu Y; Zhang H; Zhang Y; Ma L; Jin Y; Yu H; Ma B; Zheng Y; Wu H
    J Gastroenterol Hepatol; 2012 Mar; 27(3):481-6. PubMed ID: 22098411
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
    Hu C; Song Y; Tang C; Li M; Liu J; Liu J; Liao M; Zhou F; Zhang YY; Zhou Y
    Clin Ther; 2021 Mar; 43(3):572-581.e3. PubMed ID: 33516527
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection.
    Peng G; Li S; Wu W; Sun Z; Chen Y; Chen Z
    Immunology; 2008 Jan; 123(1):57-65. PubMed ID: 17764450
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
    Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.
    Amin OE; Colbeck EJ; Daffis S; Khan S; Ramakrishnan D; Pattabiraman D; Chu R; Micolochick Steuer H; Lehar S; Peiser L; Palazzo A; Frey C; Davies J; Javanbakht H; Rosenberg WMC; Fletcher SP; Maini MK; Pallett LJ
    Hepatology; 2021 Jul; 74(1):55-71. PubMed ID: 33368377
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients.
    Xun Z; Liu C; Yu QQ; Lin JP; Huang JL; Yang TW; Wu WN; Wu SH; Ou QS
    Clin Chim Acta; 2020 Mar; 502():120-127. PubMed ID: 31891671
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection.
    Le Bert N; Gill US; Hong M; Kunasegaran K; Tan DZM; Ahmad R; Cheng Y; Dutertre CA; Heinecke A; Rivino L; Tan A; Hansi NK; Zhang M; Xi S; Chong Y; Pflanz S; Newell EW; Kennedy PTF; Bertoletti A
    Gastroenterology; 2020 Aug; 159(2):652-664. PubMed ID: 32302614
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: A randomized study.
    Cannizzo ES; Tincati C; Binda F; Ronzi P; Cazzaniga FA; Antinori S; d'Arminio Monforte A; Marchetti G; Milazzo L
    J Viral Hepat; 2018 Apr; 25(4):381-390. PubMed ID: 29091327
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B.
    Ren H; Huang Y
    J Viral Hepat; 2019 Jul; 26 Suppl 1():5-31. PubMed ID: 31380584
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intrahepatic natural killer cell activation, but not function, is associated with HBsAg levels in patients with HBeAg-negative chronic hepatitis B.
    Tjwa ET; Zoutendijk R; van Oord GW; Biesta PJ; Verheij J; Janssen HL; Woltman AM; Boonstra A
    Liver Int; 2014 Mar; 34(3):396-404. PubMed ID: 23890390
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Natural killer cells display impaired responses to toll like receptor 9 that support viral persistence in chronic hepatitis B.
    Ratnam DT; Sievert W; Visvanathan K
    Cell Immunol; 2012 Sep; 279(1):109-15. PubMed ID: 23123793
    [TBL] [Abstract][Full Text] [Related]  

  • 77. NKp30
    Shen X; Fu B; Liu Y; Guo C; Ye Y; Sun R; Li J; Tian Z; Wei H
    Sci Rep; 2016 Dec; 6():38778. PubMed ID: 27941937
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
    Kondo Y; Ueno Y; Ninomiya M; Tamai K; Tanaka Y; Inoue J; Kakazu E; Kobayashi K; Kimura O; Miura M; Yamamoto T; Kobayashi T; Igarashi T; Shimosegawa T
    J Gastroenterol; 2012 Dec; 47(12):1323-35. PubMed ID: 22588246
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Relationship between the suppressor of cytokine signaling 3 expression and antiviral efficacy of nucleos(t)ide and interferon alpha therapy for chronic hepatitis B].
    Wang YL; Wu WY; You J; Yan WM; Luo XP; Ning Q; Han MF
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):27-32. PubMed ID: 30685920
    [No Abstract]   [Full Text] [Related]  

  • 80. Decreased peripheral natural killer cells activity in the immune activated stage of chronic hepatitis B.
    Li Y; Wang JJ; Gao S; Liu Q; Bai J; Zhao XQ; Hao YH; Ding HH; Zhu F; Yang DL; Zhao XP
    PLoS One; 2014; 9(2):e86927. PubMed ID: 24520324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.